These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 21593295)

  • 1. The effect of zoledronic acid on the clinical resolution of Charcot neuroarthropathy: a pilot randomized controlled trial.
    Pakarinen TK; Laine HJ; Mäenpää H; Mattila P; Lahtela J
    Diabetes Care; 2011 Jul; 34(7):1514-6. PubMed ID: 21593295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bisphosphonates in the treatment of Charcot neuroarthropathy: a double-blind randomised controlled trial.
    Jude EB; Selby PL; Burgess J; Lilleystone P; Mawer EB; Page SR; Donohoe M; Foster AV; Edmonds ME; Boulton AJ
    Diabetologia; 2001 Nov; 44(11):2032-7. PubMed ID: 11719835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of immobilization, off-loading and zoledronic acid on bone mineral density in patients with acute Charcot neuroarthropathy: a prospective randomized trial.
    Pakarinen TK; Laine HJ; Mäenpää H; Kähönen M; Mattila P; Lahtela J
    Foot Ankle Surg; 2013 Jun; 19(2):121-4. PubMed ID: 23548455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bisphosphonates: a new treatment for diabetic Charcot neuroarthropathy?
    Selby PL; Young MJ; Boulton AJ
    Diabet Med; 1994; 11(1):28-31. PubMed ID: 8181248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diabetes and acute Charcot neuroarthropathy--a call for heightened vigilance.
    Iheonunekwu N; Ibrahim TM; Ojuro I
    Niger J Med; 2010; 19(2):239-40. PubMed ID: 20642098
    [No Abstract]   [Full Text] [Related]  

  • 6. Long-term foot outcomes following differential abatement of inflammation and osteoclastogenesis for active Charcot neuroarthropathy in diabetes mellitus.
    Das L; Rastogi A; Jude EB; Prakash M; Dutta P; Bhansali A
    PLoS One; 2021; 16(11):e0259224. PubMed ID: 34748565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Arthrodesis with Total Contact Casting for Midfoot Ulcerations Associated with Charcot Neuroarthropathy.
    Wang Y; Zhou J; Yan F; Li G; Duan X; Pan H; He J
    Med Sci Monit; 2015 Jul; 21():2141-8. PubMed ID: 26205524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The diabetic Charcot foot.
    Dissanayake SU; Bowling FL; Jude EB
    Curr Diabetes Rev; 2012 May; 8(3):191-4. PubMed ID: 22429012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Surgeon's guide to advances in the pharmacological management of acute Charcot neuroarthropathy.
    Al-Nammari SS; Timothy T; Afsie S
    Foot Ankle Surg; 2013 Dec; 19(4):212-7. PubMed ID: 24095226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Six-month treatment with alendronate in acute Charcot neuroarthropathy: a randomized controlled trial.
    Pitocco D; Ruotolo V; Caputo S; Mancini L; Collina CM; Manto A; Caradonna P; Ghirlanda G
    Diabetes Care; 2005 May; 28(5):1214-5. PubMed ID: 15855594
    [No Abstract]   [Full Text] [Related]  

  • 11. Bisphosphonates for the treatment of Charcot neuroarthropathy.
    Anderson JJ; Woelffer KE; Holtzman JJ; Jacobs AM
    J Foot Ankle Surg; 2004; 43(5):285-9. PubMed ID: 15480402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measurement of markers of osteoclast and osteoblast activity in patients with acute and chronic diabetic Charcot neuroarthropathy.
    Gough A; Abraha H; Li F; Purewal TS; Foster AV; Watkins PJ; Moniz C; Edmonds ME
    Diabet Med; 1997 Jul; 14(7):527-31. PubMed ID: 9223389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.
    Saad F; Gleason DM; Murray R; Tchekmedyian S; Venner P; Lacombe L; Chin JL; Vinholes JJ; Goas JA; Chen B;
    J Natl Cancer Inst; 2002 Oct; 94(19):1458-68. PubMed ID: 12359855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cutaneous microvascular reactivity in Charcot neuroarthropathy: a systematic review and meta-analysis.
    Lanting SM; Chan TL; Casey SL; Peterson BJ; Chuter VH
    J Foot Ankle Res; 2022 Mar; 15(1):17. PubMed ID: 35232466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Zoledronic acid prevents bone loss after liver transplantation: a randomized, double-blind, placebo-controlled trial.
    Crawford BA; Kam C; Pavlovic J; Byth K; Handelsman DJ; Angus PW; McCaughan GW
    Ann Intern Med; 2006 Feb; 144(4):239-48. PubMed ID: 16490909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factors of charcot neuroarthropathy development in patients with type 2 diabetes.
    Nehring P; Mrozikiewicz-Rakowska B; Maroszek P; Sobczyk-Kopcioł A; Krzyżewska M; Płoski R; Karnafel W
    Exp Clin Endocrinol Diabetes; 2014 Jan; 122(1):31-4. PubMed ID: 24203651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infrared dermal thermometry is highly reliable in the assessment of patients with Charcot neuroarthropathy.
    Dallimore SM; Puli N; Kim D; Kaminski MR
    J Foot Ankle Res; 2020 Sep; 13(1):56. PubMed ID: 32928270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigating the Use of Denosumab in the Treatment of Acute Charcot Neuroarthropathy.
    Shofler D; Hamedani E; Seun J; Sathananthan A; Katsaros E; Liggan L; Kang S; Pham C
    J Foot Ankle Surg; 2021; 60(2):354-357. PubMed ID: 33472754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of body mass index in acute charcot neuroarthropathy.
    Ross AJ; Mendicino RW; Catanzariti AR
    J Foot Ankle Surg; 2013; 52(1):6-8. PubMed ID: 23260985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of genetic factors and monocyte-to-osteoclast differentiation in the pathogenesis of Charcot neuroarthropathy.
    Kloska A; Korzon-Burakowska A; Malinowska M; Bruhn-Olszewska B; Gabig-Cimińska M; Jakóbkiewicz-Banecka J
    Diabetes Res Clin Pract; 2020 Aug; 166():108337. PubMed ID: 32707214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.